F O R I N T E R N A L U S E O N LY

I N T E R N A L N E W S L E T T E R F O R H E E L W O R L D W I D E – J U N E 2 0 1 9 I S S U E 63

Welcome to the Musculoskeletal Newsletter. This edition comprises information on the new
Traumeel website, an update on the Bernardinho campaign in Brazil, some literature of interest
and materials that will be available in the next few months.

The new traumeel.com is online

Traumeel.com has a modern, fresh look, new features, user-
friendly navigation and functionality; it is also available in mobile
and desktop versions. Patient cases, patient views and a video
explaining how Traumeel works naturally to get you back on track
are also included.
The website has been developed using state of the art
website technology. Traumeel.com can be customized for
localization as a vehicle to augment your awareness campaigns,
deliver brand advantages, showcase the product range and
increase user and customer engagement. Affiliates and partners
can tailor their local websites to their specific needs. 
 Click onto the icon to link onto publications and websites
 F O R I N T E R N A L U S E O N LY

JUNE 2019

traumeel.ru 

Heel Russia has first-hand experience of localization of the new

Traumeel website.
Anna Slabospetskaya and Dmitry Konkin from the Marketing
Department, Russia, provide the following news and insights.
An Internet direct-to-consumer (DTC) campaign is being piloted
with Heel Russia. The key target segment for the DTC campaign
was identified as being women 30–39 years. After analyzing our
target audience needs, we have developed banners and videos
reflecting all their needs. The creative concept has been prepared
and tested in ‘live-mode’.
Each advertising format comprises a meta tag allowing for analysis
of clicks and views in real time. The DTC pilot campaign was launched
in November 2018. At the end of the pilot, January 2019, a post-buy
analysis report was provided in the website statistics report.
Content plays a major role in interacting with relevant target
groups and new audiences to the website. Regular updating is key
to keeping the website interesting and engaging. Content can be
developed for numerous sources, from paid and owned channels. A
strategic communication plan is an essential ingredient comprising
digital marketing: display ads with call-to-action, social media
marketing, blog marketing and working with influencers, native
ads, search optimization, and mobile ads.
So far, the results of the online campaign have been convincing:
the banner ads met with a positive reaction online; more than
8.5m users saw the ads between November and December. More
than 55K users clicked on the link to the website to get detailed
information about Traumeel products.
A recent addition to the website enables patients to order
products online, from the comfort of home, for pickup at their
neighbourhood pharmacy. Brand awareness of Traumeel on
YouTube increased by 13.2%. The campaign was extended in January
and is intended to run for several months longer.
Heel-Russia.ru 
A healthcare professional (HCP) section on the Heel-Russia.ru was
launched in December 2018. Reports show that more than 580
unique users visited the HCP site in the first month: 40% of users
searched for information about Traumeel.

Brazilian campaign – Traumeel

A medical and POS Traumeel campaign has been previously mentioned, featuring
Bernardo Rocha de Rezende known as Bernardinho, a Brazilian volleyball coach
and former player.
He is the most successful coach in the history of volleyball, with more than thirty
major titles spanning a twenty year career directing the Brazilian male and female
teams. “This campaign is proving to be hugely successful”, said Fabio Gaze, the
Marketing Manager with Herbarium in Brazil. Fabio further engaged with Bernardinho
for their satellite session at the major congress for orthopedics and traumatology.

Brazilian Congress of Orthopedics and Traumatology

The 50 th Brazilian Congress of Orthopaedics and Traumatology 2018 (CBOT 2018)
took place in Rio de Janeiro, 15–17 November 2018. Heel was a Silver Sponsor at this
major event. This is the official congress of the Brazilian Society of Orthopedics and
Traumatology (SBOT). Heel had an exhibition booth during the congress and held two
sponsored satellite symposia:
»» Excellence: conquest and sustainability
Introduced by Prof. Dr. Patricia Maria de Moraes Barros Fucs (chair SBOT), and
presented by Bernardinho
»» A new multi-target approach to treatment of musculoskeletal injuries
Introduced by Prof. Dr. Patricia Maria de Moraes Barros Fucs (chair SBOT), and
presented by Dr. Martin Clemens Bartsch (Germany) and Dr. Mauricio Bezerra
Uliana (Brazil)

2
 F O R I N T E R N A L U S E O N LY

JUNE 2019

Literature of interest
Injury prevention programs required
for novice runners
A study investigating differences in incidence and characteristics
of running-related injuries (RRIs) between novice and experienced
runners in the open population found that novice runners reported
more injuries per 1000 hours of running in comparison with
experienced runners.
In total, over 30% of all 4621 runners (novice and experienced),
suffered from RRI within one year. In both novice and experienced
runners, most RRIs were located at the knee (30.5%) and lower leg
(17.8%). A tendency towards receiving medical attention more
frequently was found in novice runners compared with experienced
runners. The authors conclude that more studies are needed to
develop effective injury prevention programs for novice runners.
Kemler E, Blokland D, Backx F, Huisstede B. Differences in injury risk and characteristics of
injuries between novice and experienced runners over a 4-year period. Phys Sportsmed.
2018 Nov;46(4):485–491. 

Drug-induced liver injury1
Most acute liver failure is caused by drugs.2 Drug-induced liver injury
(DILI) can result from prescribed and OTC agents, including some
herbal and dietary supplements. DILI has a range of presentations,
from mild asymptomatic liver abnormalities to acute hepatic failure.
Acetaminophen is added to hundreds of medications. While safe
when used as directed, it is the most common drug implicated in
acute DILI and the leading cause of acute liver failure.2 Half of acute
liver failure cases are from intentional overdoses of acetaminophen,
half occur from chronic use or unintentional overdoses.
Long-term use of supratherapeutic amounts is more toxic and
recognized later than a single ingestion. These patients have higher
rates of severe hepatotoxicity, liver-related complications, and death,
compared to those who have overdosed with acetaminophen
ingested in one dose. Most patients with acetaminophen-
induced acute liver injury present with undetectable levels of
acetaminophen especially those with accidental overdoses.3
1. Reau, NS. Medscape Gastroenterology 2019. 
2. Chun LJ et al. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol.
2009;43:342–349. 
3. Leventhal TM et al. Acetaminophen is undetectable in plasma from more than half of
patients believed to have acute liver failure due to overdose. Clin Gastroenterol Hepatol.
2019 Feb 4. pii: S1542-3565(19)30087–4. 

Review of guidelines for non-specific low-back pain

The number of guidelines indicates that there is no magic bullet, there are
unmet needs and a place for other approaches in low back pain (LBP) treatment.
A group reviewing 15 clinical practice guidelines for the management of LBP in
primary care found that, although the number of randomized-controlled trials
has nearly doubled since 2010, the recommendations regarding management
remain similar compared with a previous review in 2010.
Some differences were identified regarding the recommendations for assessment
of psychosocial factors, and the use of some medications (e.g. paracetamol), as
well as an increasing amount of information regarding the types of exercise, mode
of delivery, acupuncture, herbal medicines, and invasive treatments.
For acute LBP, most guidelines endorsed recommendations for patient
education, reassurance about the favourable prognosis, advice on returning to
normal activities and avoiding bed rest. The use of NSAIDs and weak opioids is
recommended only for a short period and only where necessary.
In addition, referring to a specialist is recommended in cases where there is
suspicion of serious pathologies or radiculopathy (pinched nerve), or if there is
no improvement after 4 weeks to 2 years.
Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back
pain in primary care: an updated overview. European Spine Journal Nov;27(11):2791-2803. doi: 10.1007/s00586-018-
5673-2. Epub 2018 Jul 3. Review. 

3
 F O R I N T E R N A L U S E O N LY

JUNE 2019

2018 activities – a brief review

Workshop at the European Congress of PRM, Vilnius
Almost 30 countries joined a teleconference on 14 March, 2019, to hear highlights
NOTI
CIAS
DEST
ACAD
AS DE
2018

from the Injection Techniques workshop by Dr Dalius Barkauskas delivered at the

European Society of Physical and Rehabilitation Medicine (ESPRM). •
•
•

Debe
•

*Rigidez
DIA
> 45 años.
Dolor
en

conside
matutin
GNÓ

rarse la
STIC
DE O

Rigidez la rodilla relacion

matutin
a < 30
minuto

posibili
STE

s.
O

ado con
OAR
TRIT
Agen
IS 3
Elija tes tópic
activida

Calor
agen
ICE d física.
tes os
(Hielo tópic
,
si el Compresión
IEN

•
TO

•
os para
Y R
EC
TR

OM

TR
AT

EN
DA

ATr14
AM

CIO
Intr
odu
St.
The

NE
St.
Laur
Laure

S
ctio
nt
Instit
en
ute
tG1
(SLI),
Vanco
,To
ma
1
Diff
ere
ntia
l effe
reumat
I 2, Ta
cts
a > 30 dad de el tratam TA uver,
oide positivo minuto artritis dolor
treat isM n

Participants were led through the six video

WA,
inflama musc , Elevación) iento year IE
a com
/anti-CC s, anteced deentes toria. * ular inicia men N
binaT O
USA.
cket
¡Manté

of T
2
The

• La OA esngase
P.
• AINEser necesfamiliares, aument está cerca tras l s. Prev t of acut tion I N I
effec
el ejerci e mus of dilutC I A
Georg
t MR
alerta!
• Agentestópicoario, añad ious e Wash
de la facto ts,
L
• Las radiogrcada vez o de PCR/VH articur cio
whic ly
alpho h may publ culo ed plan
ingto 1
, Zh
r14
a
S,In factorlacióna una
n Unive
más frecuen (debe tópic
• La enferm afías pueden
ished skele
te en pacientusarse os natur this (TNF exace
resu
-α), rbaci
tal
t and
lt fromin vitro cond mine
rsity ou
esto no edad tibiofem presentarSi toda duran
es más te ales Traum
heal stud andón J 1, Medi

Ri M
vers
and ition ral cal
una imagen sequ ing, colley, we inter a decr extra Cente
sentido ocurre en la oral dos
jóvenes in s,
vía eel®, enci exam leuk ease vivo like spra cts r, Wash
enferm a menudo se hay sínto ,sema
por nas ng cting 1,3
• anterio
Los signos r. Puede edad femoro present mas,.
normal ej., para Me
trasZeel®
una, Capsa
podetho
to
ined
exam samples the
in 8 in stud
(IL-8) secre ies ins
that
and has been
ingto
n, DC, , Vy

u
haber
hinchaz rrotuliana,
a con avan lesión.
r dsicina
ine effec
at y de ser
.1 tion have
dem traum
USA.
atk

s dic
molesti
as en Female ver los gene multAgen ts of
of used
in Y 1,3
3
Acade
ón y restricc en la que ce al neces inter onst atic
ión en el dolor paso la línea8–10
wou
nd de-wee
sesigui
bene
ficios
expr iple tes Tr14ario,
essio time
Parac orale and consi
leuk
in 1
rated injur wide
•
ies, ly for
mGen
e LLC,
, Sh
Limít el movim Tr14; inflic
siente
la
enteted. articula ) Agen etamn chan poin s diclo dere •
beta its anti- for the Novo

lofe
ese
k, Russi to
daily topic k-old ción,
de forma ts and fena añad (IL-1β infla over
al uso iento. pero tes olges(nota Res sibirs
Pacie
AINE/ ntes • “segú
n sea
T Rstore
dA
al
A T (Figure diclo ExperimeICR másmicedifusa
natur at : riesgo c
usin in
ales:unpr g nexta mou
ir ), tum mma 60
tory ults kalo
• Comb
fena y or a.
All
sam in M RNAI E Mice c [2 ntal were en
1). Traumeced hepá
D 1,3,
4
agen de se A.P.

nac
nece -gen mod necr The
bajo ente ticoerati Ersho
Cons laterN T Owere mg/ml]) menanestheti
mou treat osis
inació te selec sario” ples eel®, into COX 4
de bomb tivo
riesg
o were ,se geno were
moni iderepend Asacri
ing V Aficed
d depty GI)on el of
Zeel® wou bioa /LOX
v Instit
, Je

modules which included workshop highlights,

n
pson
and ts (s.c. zed, of ute
a de con inhib de COX- gene conv toree me sequAINE
RNA N ZatA corre
h and sing
le-m nd PGH ctive path of

on
Inform
erted (mm al ence orale Tr14 their trans agen ways
Pacie protones idores 2 studentexpressio to pacie D Ospon injec back repro olec synt
T,
atics
10). nted on sisola vario of cript hase ts (Figuof eicos
ntes (IBP) and PacieRPK1 ~3 regul tion, us ding tion s shav duci ule COX Syste 1
p-va t-test. n anal ntes0M billio SeqL
a by
dow 2 (COX Cesn
COX
bility
arme rRNA time poincont near ed, later ms
con -2 re anoi
•
SB
mayo lues mayo Tran yses con (read n SMS L Sing nte, depl rol and . LTC4 and dow nstre -2) 2). ds RAS,

•
r riesg Cons
calcu scrip
idere
r riesg, the s read leaseso etion ts, and
o GIlog2 per kilob s wereMolerándo
treat the wou a
nd 1 cm 2
synt mRN In
nstre am PGE2 A untreate lve
invo Novo
201 ule
8 H vicius
o GI latedCOX-ts were men hase 12–2 sibirs

/LO
seve
Ácido Las
inyec •Wou
Evite
y CV 5
y/o
treat
with 2 map ratio
con ped was ase per gene Sequsobre
cule le(Ribo ~50
Zero mg skin
ts were site
plus
abra
sion
mRN
am
PGE2 (Figu 4 hour wou ral
d
cata
k, Russi

(el uso hialu

IGH K,
a. 5
cione ndin
losg AINE/ mayo Fishe IBP rated ence los ) and appl topic A level . Tr14, re
3). s after nds, Biolo
depe rónico Tr14 men calcu 10 riesgo colle ied s (Figu how Diclo RNA lytic gisch 5

X pa
s intra injec contr agent mod r riesg r's to
exac gene lated millionPacie al seq conv
L I G Seilh
la prepa nde . The r (SMS cDNs cted twic COX injur e Heilm
Si toda ració de
Tr14 -artic tion
injec ulare
ol alitieo renal
tes selec t test. onto , andmayo
Cons • read ) and A synt and e
align ntes path re
3).
ever fena
, did c bloc due
y, dete ersio
ittel
ed con cted ns
H T eim
s s for way
vía hay n) Topic tion s pued tivos o medi logy idere p-va r riesg align hesis Diacylg
not ks to
feed of Heel

• de COX- cado riesgo(GO) grou

read
o s). each ed to . 2 a arac
Phosph
bloc that
S er B
GmbH
back stron

thw
al diclo + ointm unlues lycerol
Traum en ser were CV
sínto Salin AINE olipase
k COX feed hido
s con CV, For trans the
(COX-1 or phosph
indu g indu nic
, Bade
mas, e contr fenac más Expe
(pued enteel® 2 antic porpsej.,withcon
or -2 PGH Arachi C Phosph olipid
calcu diffe cript -2 induback n-Bad 5
avan ol perío e usars & Zeel® adecu 1 rime
napro meno
and
by ction ction
acid
, Mc

юм
synthasPGD synthas donic
oagu latedr renti
2
peroxid olipase en,
ce al adas Anes ntal ction direc of the
lante ExPlxeno
acid Germ

ays
al e e

Caffr
Prosta ase) A
dos e proto
prolo durante
TE paso en estos ain with PGD
, but t inhib
2
Exam any.
R theti s softw glandi
SNRI A P I A S col 2
Lipoxyg
sigui ngad
PGE
did ition had ining
ey
ze nH
2 pacie (FLAP, enase

•
synthas
: Dulo F A R 7 animente os) mou are (PGH atten
T Shav Figur 2
ntes GGT an early the
•
Alox5)

TA
6-keto- PGE
R

rev
e HPETE
Para xetin M A C AT free e dorsa Cortic se e 2. PGF )
uate

e
2
PGF 2
level

synthas
AM als/tr The (hydrop
This 1, whic , stron s
Opio uso regul a
2

OL Anal endoth
2

e
of hair l
1α

1 cycloo

synthas
eatm LOX of
•
ÓG eroxye
IE (uso osteroids
elium
ides skin ysis
Diffe com Tr14 h the

an interview with Dr Barkauskas and modules

yclin
ICA NT 3 xygen path g
y gaba ar
icosatet
ent effec are requ inhib leuk

eale
Uso limita expr** rential
•
S Abra

Prostac

oxane
a O ase Prostac
HO
raenoic way
for pare itory otrie
Recu corto pent DE de do) essio gene and yclin LTB acid)
repre d with t was ired
2

Thromb
shav lipoxy (PGI
effec ne
CA
4

y inoid 4 n mRN
mayo erde que largo plazo es untr susta for the
)
ed genas
2 Glutath Leukotr ssion conv
SO
Thromb
IN Treat area A was t

800
prod on the ertas
• TE eate ined
ione iene
e

0M)
of

db
r riesgo los RV S GR posit with 2 (COX/L oxane
Glutath A
indu LT enzy d
riesgo La elecc E N C cont from uctio level es, it
(TXA 4
Netw

(RPK1
OX)
A Vive or Tr14
Glutam Leukotr S-trans ione-
contr ) platelet
de caída s I Prost pathw
2
ced
rol 12–9
pued ión Ó N Q U s of was

600
PCR, inclu 0, ols E nega onto orks s ic acid iene ferase
by mes n
is the wou 6 hour of LTB4 LTA4 appa
Prost
aglan
S tive

400 ssion
del ays.

y RN
proteín s en yen12, logy and Thromb C
2–3
locale e variar tiemp 5
GI, gastroi 7 time IRÚ aglan Source
4

140
din
aC los ancia un (GO) gene indu nds
•
Leukotr
24, Harv
R oxane fold , LTC4 hydr rent

Expre
SNRI, s,

m
reactiv
inhibidntestin 36, poin s entre o y GestI C A G/H
din : https: (TXB iene
in Tr14- ction or diclo lead olase that
a; VHS, nos 72, 96, tsLa artropy áreas los6 los proce synth
G/H ing , and
D
** Nótese ores al; COX-2, tissu //en.w )

120
2
3 Leukotr 4
Leuk Tr14,
velocid + 0H
lastía espec distin
synth treat of Nrf2 fena LTD4 , micr

0M)
de la cicloox adFigur 120,adecu Isola e ncRN ase ikiped otrie to
dimie iene
c-tre an

200
Leuk osom but

Ase
cartílag que recapta tos 2
se reseríficas
ase ed

(RPK1
E
,
ygenas de esedime and adam RNA te andpacie A expr ia.org wou (Figu ated overall resp

100
los riesgos
o, condro ntos 2
4
otriene not
ción a-2; 1. Studyntación 280 192 de /wiki/ A4 ectiv al GST3 diclo
hour ente a purif ntes, espec essio ne
toxicid de los de seroton va para la o las hydr nds, re wou redu

ssion
IBP, Eicosa A4
metho ; anti-CCsamp médi as 5), and nds. ction ely (Figu , and fenac,

0
inhibid íficos n

80
ad. cortico ina–no or dolog s las
7
medi
y
quien articu 4 cos, noid hydrolase

q
les Gene show

Expre
Use esteroi Diffe olase(con RNA A know of
las inyecci repinefde la y P, Anticu das es no lacion pauta 75–8 re 4).
0H
tail rate n in

60
des bomba
outlin renti (conv
verts seq
ones incluye rina. erpos
e.de proton antipép cDNA and no quirú respo es afect al splici s Figu confi n mec 0%
ertsLTA4
con n
cuidadsepsis, 8 rgicas nden adas ng 12H re rmed hani

40
es; tidos Sequ LTA4to 6.
o en exacer CV,
cardiovcíclicos
SeqL ence 5 contro toLTB4
LTB4) that sm
pacien bación RNA 24H

80
Tr14 l

20
tes tratado
tras ascular citrulin
L on editin ) Nrf2 THU
; SMS ados; Helic diclofe

0M)
la inyecci 36H 002
s con AINE, os/ g Hours nac

(RPK1
0H
1

60
ón,
anticoa antiinfl
hiperg 6 Leuk post-i 72H
gulant licemia amatorSyste otrie
Leuk Oxida

ssion
on lifestyle and activity, injection techniques
njury

600
12H
es. , hiperte iosms
no esteroi ne
otrie contro antioxid tive

40
Micro stress

20 Expre
nsión Biolo C4
ne 96H
Tr14 l ants
gydal; synth
C4 24H

500
transito Micro
soma diclofe actin
synth

400 0M)
ase 120H
soma
l gluta nac
ria, degen ase ROS
Electrop

(RPK1
36H Keap1
l gluta
thion Hours
eración 192H Differential hiles
Const
e S-tra post-i 72H
Nrf2
thion effects of

ssion
del

0
itutive
njury
diclofenac Tr14 versus

300
e S-tra actin
nsfer

200 Expre
DI nsfer on COX/LOX Keap1 condi
Figur AG 0H ase 96H
tions
of COX-2e 3.
8 days >and45 •
Transc
NO
S I 12H
3 (conv
ase revealed
3 (conv by120H
RNAseq
pathways Nrf2 Nrf2

POC •
Cul3
S O erts Figur
(192 LTC4year
Activ ription erts Ub

100
contro LTA4
St Laurent
e 5.
Ub Ub

K N E EE T • hrs) synthas.al chang F O24H Ub Ub

G 1,Toma 2
TR Vyatkin 1,3 LTA4 192H Ub
Molec
Mor ity Tr14 l to I , Tackett MR 1,
GUI post-i se Y ,
ST Seilheimer Shtokalo LTC4
ning relat
EA to D 1,3,4, Jepson Zhou J 1, Ri M 1,3 ular proteas
njury. were es in COX/L E O36H diclofe LTC4
DE
B 5, McCaffrey )TA 2 T 1, Cesnulevicius, role Nrf2
ed quant AR TM nac ) of Nrf2
ome

stiffn knee
0H

O S T E•
Hours K 5,
ified OX during
Maf phase

joint T H72H
post-i EN protei antioxidII
Con ess
Diagnosis
enzyme
by njuryR I T
< 30 RNAse painTr14 and n. Source
12H ant
*Mo sider TI s
protein

OAR

150
S3 AN contro ARE

350
and rning infla min q during . diclofe Top 96H s
: May
Manageme

300 0M)
D 24H Tr14 l cytosol

stiffn mmator utes contro nac Cho ical Gam OL,

0M)
T H R I ••
Nrf2

(RPK1
. l, Tr14,therap RE ma-g diclofe Cayma nucleus

ose age Gam

120H

nt•

(RPK1
Be , nucle
Nrf2,
ess CO 36H nac n Chem
aler > 30 y arth Ice, and y.top
Using nts lutam
ma-g Hours

ssion
100
TIS
nucle
ar
OA t! M ical

250
Hea comdiclofenac

ssion
lutam facto
minu ritis. *
192H
RNAse
ical yltra post-i 72H ar
M 2012.
•

Expre
facto
is tes, t if pres treatm ageq of abrad EN nsfer
yltra njury r in

50 Expre
X-ra incre rKEAP antioxid
mu sion nts nsfer
ase

200
fami in
•
reactive
DA

and safety, and shoulder and knee injection

96H
asin
Join ys may
ent. ed mouse 1 (conv KEAP
2 path ant

gly ly ifhisto scle , elev in

RNA
ase respons
oxygen
initi TI 1 (conv 2 path
nee
• pain IN way e elemen
levels
pain t line tendbe normcommon

150
erts 120H species

Top ded ry, raise atio al skin, the IT O

N way
nea n areman erts
LTC4
•
The St. Laurent 1 (ROS) t (ARE)

• Late is felt erne al at in youn Top ical add d CRP/

shown levels
r join (ICE ageover IA S LTC4to The George 2 Institute
192HWashington (SLI), Vancouver,

100
L LTD4
to AcademGene 3
University WA, USA.
)
r sign mor ss pres (mu ical NSAID afte men LTD4

0
Medical
ESR,
LLC,
t M ) A.P. Ershov InstituteNovosibirsk, Russia. Center, Washington, DC,
4

s inclu e diffu is ofte entationger patie r exe t ) Biologische Heilmittelof Informatics Systems USA.Figur 0H
st be natu posit A
5

N RNA e 6.
de bonsely andn present . ive rheu rcise Figur 0H Heel GmbH, SB RAS,

nts ral age AG Tr14, levels Transc

Baden-Baden, Novosibirsk, Russia.
12H
use enzym e 4. Germany.
or diclofeof Nrf2,ription
y enla ante Ifinstilltibio d–fore.g. nts: mat or es areTransc E M 12H contro
DI afterTrau oid in
flare shownription
al E
contro Con al
nac a key system 24H Tr14 l
SE rgem riorly. symfemo 2 wee
injur facto during systemN T 24H Tr14 l clu treatm regula s differe diclofe
At initi A S E ent. Swelling pto ral ks meey.l®, r/an 8 days s differe diclofe sio ent. tor of 36H nac
the ntially
Hours
ma dise for ti-CC ■
ns
• nac Tr14
36H
M andtic, ase benefitsZeel®, (192 ntially Hours oxidat affect post-i 72H
Prior al diag A N A P.

UK
pro but
restr hrs) repa and ive ed by njury
post-iaffected
post-i 72H

87537 18/06
Cap stress Tr14
Note itize educnosis: G E M
diclo
ictio not pate
gre to
be saicin
njury. by
njury ■
Diclo ir, as pathw and 96H

Prov that unco ation

ide
• EN
T 3–13
•
ssntomay
the be llofeseemor n)
Tr14
and
diclofe
96H
■
prod fena measure c impa
Tr14 uctio c, but
fena

d
ay, arediclofe
shownnac therap
120H

educ ntro about NSA Low

• nex pres ct
120H
Res if furt nac not by mRN diffe
t step ent. al dise
as a y.
therap by , but n. 192H
Con ation lled OA, Com ID/C risk trict
A ase, Ora her y. RNA activ not Tr14 rent functi Induc
on of tion
, inhibA leve
•
192H
tinu
In OA e to • and coexistinoptimize
advi
bine OX-
with 2 sele ient
pat to ‘as
requ
D
VA whe Paral age needed
re the ceta nts •
levels
of 3
Refe ating diclo
the fena its ls.
subs
yste
time of Nrf2
after by
enco of the monitor ce throgPat 1. Porozrenc
mor lifestPPI ctiv ired N
CE Nat , con major Nrf2 c, redu COX ms Tr14
injury in
yle e age from ov es -2 mRN in with injure
ughientbidities beha
Note urag ural mo side leukot /KEA the
knee the ’ use

techniques.
D age l (no r add 2004 restinS, Caha ces COX contro d skin.
, mo Con
riene A indu
: In e nt P2 mRN
an overweight , the mospatient: verb with may viors M 2. St l, or
for each al and nito side A nts: te: ing synth ;11(2): g
Laure 143–9and
lon path A /LOX with
incr prom , cont
ction
Osteoa gain step. weig loss t imp r pati r ora
N
AG Trau hep etic TA,
Geno Kapra G,
nt
L,
activa Weise way. leve path
rthritis easwritt ote rol mee atic . ted r M, ls in by way
The lifetime (OA) is in overall An aver ht indivif appropriortaHya nt mod • ed en dise co-e
GI inter ase progxistinPat
ent l NSA EM l®, and
Disc mics nov Shtok
The losu 2012;1P. Intronalo D,
huma Brans the
leuk
bloc
king s duri
Provthe leadinfunc age weigidual,
n immuki D,
women) 1, 2 risk of develop g cause
ate.
(useCon luro ifiab In + CV vent incr g med
Conressi ient
regu ID
larly• EN
T
Zee GI
l® risk) Tim studi res
indeb McCa es wereand
3:504 ic Tacke
RNAs tt
Lider
nocy O,
otrie dow ng
wou
diagnos
. This ing
pocket Perfo symptom
ide
advi • tion.
of muscuht
losin
upo
loss gnaprep
dep nic add
sideacid ition le
pounend r dieti risk facto
risk
,
ion. side
•
eas
on.ed
r COX GI cond
with
ical and ted ffrey fundeackn
.

owle
constMR, Erem
itute
tes Ober
by
the baum
ne
synt
hetic
nstre
am
nd
ce Avo and
to has
ition counse
is guide rm ina PGE
osteoart and manage activ aims mod onatic knee OA If still of loskele intr the receiv d jointl home M.
5% aratd resul ent risk the T, Wahl

Cont
dge path 2
cian a-arr in id /or
•
vision
ment ities to erate provide exer sym in overtal ion) pain
-2 s. ed y majo opathInhib
hritis of cise is estimate refer ticuman NSA incr with l pati speakby Biolomen r fractiested way,
ition
Walk of of
clinician pto d to be weig in aand
the ts
•
OAthat the inten Dr ic medi of
other joints. ts
4lb disabil ral. lar y patieID/C eased t likel
Avoi ing is of are
ents
on C, Urcuq
knee. sity: PPI ent Georg er
hono gisch IL-1be
PRIN with a ma ~45%ht ityctio nts OX-2 ren on EUL of cation y
• inje es
bene not P HThe and in (1.82
(40% St. raria e Heilm the
non-cui-Inc
ta
CIPL
Perfo d high same
aero principle tic,
simple is obes risks AR, Traumand
•
Laure from ittel
•
OA is a
ES
stren rm ‘core‘impact l in knee
ficia pain
SNR ful. A RM bic
activ s can begre
pro but thoroug e (ma obes men kg)
and 47%
olde redu
ns sele al
ctiv risk Am nt,
who Biolo Heel
oding
hima
eel
TNF-a

• Trau in S, S. Clin lpha

ity.
•
OA can
heterog
eneous gthe and activ
I:
For Dul C O L
A
ity for applied
ss to h overview
y be ction
r patie mee
may
eHen or
agece me Con incr ient
Pat
• ste
rda
sadlygisch Gmb
RNA Seilhe
in mamimer Dev secre

APOY theto manage periof the in be e H

phys disease Opi ityregu OA. oxe O passe Heilm and Immu tion

ADO • affect
Early diagnos all age ranges. ical ning
ther with
loca oid
of manyShol stren •
(run tine G I C A
s larning
atMleast nex ment of nts l® &kneemore
use
ods dbrou Zee -join suit
nts dica
ting
side eas
CV r NSAed CV
with m,
The d durinittel the St.
B,
malia McCa nol

ES
Heel Laure n cells. ffrey

POR U is is importa apis all majo subsets.

rt termand • use L A 150 t step for ght
of exte an t load
l® able with risk risk Net g the Gmb

B E CPR
gthegab , jump A T T N e.g. ID with comp H. nt Institu BMC
nt. t for Note r mus A G min tim nde 18% her
NA ning in ant letionThe authote.

AM
Prioritize advi risks cle
falls or apeexer ing) in M P T
E
E M utes per e) d man icoa naproxe low lan Profe

20U18 • a
Manage holistic P A approac in ce. incl long
elde udegrouterm ntin cises knee S EN y pati gul er ds, of
these rs are ssor

ED IN wee ant n 13–

The teleconference session covered how the

ps oids for
C••A. T I V •
ment focuses studi deep
h to GI,CRP, C-rea OA. k– ents
Manage
pain andPain MonA N managin• gastr
g the patient
rly incr at useleast the
T
O choo s 16
Jun
es. ly

.... •A DE Minimiz
• e risksenhance
man educatio
treat
A GSNRI, serotointective
E Mn, addressi prote
ease 2–3 arthritic S U R F
SE se a
varie
Cor
tico e, 201
.... BIOLO of
agem ** Note
specific E onin stina in;
ng
with clinical d risk time joint Cho GI
V (lim ster
Litera Cho interven entUsepatholog
risks N –nor
T COX- associat
l; s per C ty 8
• .... OA: ER
functions. ESR, of of ited oids
GISCH Osteoart Fully ose tion isinjecperf of iesepine 2, cyclo
tions corti involved
eryth ed risks, weepati daily ice A L I
E use **

ture .... E HEI • cartilage

hritis can counoptions . orm phrin oxygrocyt
ed to e reup enasthe
judic coste
in e disease. optimizi
ng load Arth join k.ents
t(s)Con, clin
ofand N T
tim gene ER CA )
.... LMITT be defined
surround loss, bone remodeon in
sel with iousl roid
sedim
and mechan side e and ral VE SE
summ
affe ician r N
.... EL HE
the
theseveral supp take e-2; PPI,entat
y in inclu ade rop cted consspecific
qua last ics. s, locaultat
bodTI
Oy S

Sum
risks grea
.... ing soft
pa ways. OA patie de sepsi ort inhibitors. protoion rate; N
tissues. ling and of test riskis a disease the tely y rese
aries ge E L G M B H l guidionprowith
nts

Wor
addition
.... Osteoart ‘Clinical
osteoart interalvent response
on s, post patie n-pu anti-
bene anticoagu ofinjecthe nt, mp inhibCCP, to
non rved
ced
elin ures
ksho .... .... joints or
hritis can hritis’ is ions sfitwithin tion whole
ratio lantsthe
to joint,
flare, prom
anti-
-sur for tho es
a
and can
.... .... the patellofeaffect any when. symptom
. . synovium CV,principa
itor; cyclic
ote citru lly involvin
gica se
spe vary
p at
of the
....
hype
rglyc , capsule suita
moral joints. three compart s are present. cardi l mea who cific bet
g
....
llinat
ovasble and
....

2018 mary o
sure hav area wee
ESPR
aemi ed other
ments cular phys
....
pept e not
.... .... of the
knee; the
a, trans ;
icalNSA
ide; s s of n

M ..
activ resp
. . .2 medial
ient

Prese ....
IDs,
and/or rtens
hype ity and
non- ond
lateral ion, ed

nter .... .... tibiofem stero to

.... .... cartil oral idal anti-

workshop recordings can be used by our colleagues

age

profi ....
....
....
....
dege
nerat
infla
mm

Trau le . . . .... . . . .3
ion,
chon
atory
drug

high f
.... ....
droto s;

mee .... ....

xicity
.

l – ge ....
....
....
....
nom .... ....
Trau ics stu ....
....
. . .4
mee

light
l – in dy. . ....
.... In th
is
Cong Highlig
flam .... ....
.... ....
Liter mat .... . . .5 res ht
Vilniu s of Ph s Newslet

s
atur ion ....
reso ....
e of

in subsidiaries and partners, accompanied by the supporting

.... s, ysica ter ed
inte lutio ....
Heel 1-5 Ma
y 20 l and
rest n... . .... ition
Knee .6 on
oste ....
....
....
.... Disord Injectio 18. There Rehabil we co
ver
oarth .... .... ers. n Tec ita
ritis ....
....
....
....
.7 Ot he hniqu was a sci tion Me the 21st
pock .... es in en dic Europ
et gu
....
.... comp r poste the Ma tific wo ine (PR ea
SU ide . ....
.... ris
proje ed: addit rs an d nage rkshop M) held n
.... . . . .7 ment su in
PP
OR
TE
....
.... an
ct pr
es ional ab str ac of Mu pported
.... d fin ented bioinf ts at

2018 highlights material, that was distributed to the countries.

D B .... sculos by
Y A
N E
....
. . . .8 Front dings on at EULA ormatic inter
natio
kelet
al
DU iers th e pr R, held data na
CA
TIO Litera of Scien omot in Am of the Tra l co ng
NA
L G summ ture on ce confe ion of sterda umee re ss
es
RA aries a ren infl amma m, 13–1 genomi l
NT are pr selectio ce, New 6 cs
FR
OM ovide n of
ab York, tion resolu June 20
BIO d for str 25 18
LO intere acts, po –26 Ju tion at th

The 2018 Highlights are available in English, Spanish and Russian,

GIS ne 20
CH st an sters e
E H d fur 18
EIL
MI
ther and guide .
TT readin lines
EL
HE g.
EL
GM
BH

and so will be the workshop recordings.

Traumeel new data: posters and abstracts THU0021

Differential effects of Tr14 versus diclofenac on COX/LOX pathways revealed by RNAseq

Two abstracts (one abstract also as a poster presentation) on St. Laurent G1,Toma I2, Tackett MR1, Zhou J1, Ri M1,3, Vyatkin Y1,3, Shtokalo D1,3,4, Jepson T1, Cesnulevicius K5, Seilheimer B5, McCaffrey TA2
1
The St. Laurent Institute (SLI), Vancouver, WA, USA. 2The George Washington University Medical Center, Washington, DC, USA. 3AcademGene LLC, Novosibirsk, Russia. 4A.P. Ershov Institute of Informatics Systems SB RAS, Novosibirsk, Russia. 5Biologische Heilmittel Heel GmbH, Baden-Baden, Germany.

additional bioinformatic data of the Traumeel Genomics project

Introduction Results
Examining the levels of the leukotriene convertases, it was apparent that Tr14, but not diclofenac,
Oxidative stress Constitutive conditions
Tr14 is a combination of diluted plant and mineral extracts that has been used widely for the The COX/LOX pathways of eicosanoids involve several catalytic conversions of arachidonic acid had an early, strong inhibitory effect on the levels of LTA4 hydrolase, microsomal GST3, and
treatment of acute musculoskeletal conditions, like sprains and traumatic injuries, for over 60 into bioactive agents (Figure 2). In untreated wounds, RNAseq detected a strong induction GGT1, which are required for the production of LTB4, LTC4, and LTD4, respectively (Figure 4). antioxidants ROS
Electrophiles actin Nrf2

years. Previously published in vitro and in vivo studies have demonstrated its anti-inflammatory of PGH synthase 2 (COX-2) mRNA 12–24 hours after injury, due to feedback induction of the This Tr14 effect was sustained from 12–96 hours, leading to an overall reduction of 75–80%
Ub Ub Ub
actin Keap1
Keap1
effects, which may result from a decrease in secretion of interleukin 1 beta (IL-1β), tumor necrosis transcript by downstream PGE2 (Figure 3). Diclofenac blocks that feedback by direct inhibition compared with untreated control wounds or diclofenac-treated wounds. A known mechanism Nrf2
Nrf2
proteasome

S2
Ub Ub Ub
Cul3
factor alpha (TNF-α), and interleukin 8 (IL-8).1 of COX-2 and downstream PGE2. Tr14, however, did not block COX-2 induction, but did attenuate for repression of LT enzymes is the induction of Nrf2 (Figure 5), and RNAseq confirmed that Nrf2
later LTC4 synthase mRNA levels (Figure 3). mRNA was induced by 2–3 fold in Tr14-treated wounds, as shown in Figure 6.

were accepted by EULAR.1,2

cytosol
In this study, we examined the effects of Tr14 and diclofenac in a mouse model of wound
nucleus
healing, collecting samples at multiple time points and using next-generation single-molecule Leukotriene A4A4
hydrolase (converts
(convertsLTA4
LTA4totoLTB4)

S2
phase II enzymes
Diacylglycerol or phospholipid Leukotriene hydrolase LTB4) Nrf2 antioxidant proteins
sequencing to examine gene expression changes at unprecedented depth and reproducibility. ORIG control Maf

140
Phospholipase C Phospholipase Ae2 29 LOX pathway INAL
COX pathway Arachidonic acid
Volum
HPETE (hydroperoxyeicosatetraenoic acid) TraumTr14 A R T I C L E
Methods ankle diclofenac
eel vs.

120
Lipoxygenase
PGH2 synthase (FLAP, Alox5) H2O ARE
antioxidant response element (ARE)
2013 randommobilitydiclofenac
(COX-1 or -2 and peroxidase)

Expression (RPK10M)
reactive oxygen species (ROS)
April LTB4 Leukotriene A4

100
me
30 PGD
synthase
Prostaglandin H2 (PGH2) Glutathione- ised, after for red
Female 8–10-week-old ICR mice were anesthetized, their backs shaved, and a 1 cm2 abrasion Volu Glutathione S-transferase C. Gonz blinded acute ucin role of Nrf2 protein. Source: May OL, Cayman Chemical 2012.
Figure 5. Molecular

Thromboxane synthase
PGE
, con ankle spr g pain
alez

Prostacyclin synthase
PGD de Vega,
synthase 2

80
Leukotriene C
wound inflicted. Experimental treatments (s.c. Tr14 injection near the wound site plus topical 14
4 1
C. Speed trolled ain and
y 20 PGE
and : A mu imp

Dr Bernd Seilheimer (Heel) also presented findings on the

Glutamic acid , 2 B.
Tr14; topical diclofenac [2 mg/ml]) and corresponding control treatments were applied twice Ma
2
Wolfa
non-inf lticNrf2, rov
nuclear
ing factor in KEAP2 pathway

60
PGF Leukotriene D
rth, 3
J. Gonz entNrf2, nuclear factor in KEAP2 pathway
daily (Figure 1). Mice were sacrificed at various time points, and ~50 mg skin collected and eriority re,
2
4
alez 4 control
TRAUM trial Tr14
AL SUMM EEL The evidence
SUM

40
stored in RNAlater pending RNA isolation, rRNA depletion (RiboZero) and cDNA synthesis. com 2 endothelium platelets
CLINIC ®.. MAR

ojournal.to the
Y

350
6-keto-PGF Prostacyclin (PGI ) Thromboxane (TXA ) Thromboxane (TXB ) Leukotriene E
1α 2 2 2 4 Backgr
diclofenac
All samples were sequenced on a SeqLL Single Molecule Sequencer (SMS) and .cmraligned ARIES for base topical ound: Acute

Expression (RPK10M)
www Traumeel

20
This diclofen ankle
ac gel sprains
0H ®
trial
mouse genome (mm10). ~3 billion SMS reads were generated. The reads for each transcript Inte

300
Figure 120Hnac gel aimed has
59 2. The cyclooxygenase and lipoxygenase (COX/LOX) pathways. Source: https://en.wikipedia.org/wiki/Eicosanoid
12H 24H 36H 72H 96H 192H to compar proven are commo
rnat
(1%)
Hours post-injury tive, efficacy n
in alleviatiand activity iona
were converted to RPK10M (reads per kilobase per 10 million aligned reads). For differential 3–9 multice in the managee a topical l Jour
95 involved ntre, natural ng pain limiting nal
5: within 449 physica
random ment of
acute agent, Traume and restorininjuries, of Gen
o.

250
ised, Open
What’s
gene expression analyses, the log2 ratio was calculated, and p-values were calculated with , N Prostaglandin
Prostaglandin G/HG/H synthase
synthase 2 2 Microsomal glutathione
Microsomal glutathione S-transferase
S-transferase 3 (converts
3 (converts LTA4 LTA4 toointmen
LTC4)
to
the past
LTC4)
lly active blinded ankle el with g function
and Access
eral
30
Traum
t (T-O) 24 h. Particip adults , active-c sprain. • A range known Full Text
topical Article
Med
ol.

600
(n = ontrol Methods: .
ants controlng unilater and
sustaini
, V
147), (n = diclofe- for reducingof therapeu icine
student t-test. Transcripts were mapped to gene ontology (GO) groups with ExPlain software control
anti-i eel – an
adminis 152) or This
14
6-week were tic intervent
al grade non-inferiorityprospec-

200
LIN Traume random stability pain
20 Tr14
s follow tered and 1

, BER
MEDYR
logue topicall el gel ised • Topical in patients swelling ions is available
Tr14
ay
Tre to receive 1 or 2 ankle study
up. Results

accepted poster on inflammation resolution at the New York

Clinic,
and p-values calculated with Fisher's exact test. Scale (T-G)
y to with and restoring & Rehabilita

AR 2012 nfl
Sports

em
diclofena
M
groups, pain : Day the ankle (n = 150)
7 diclofenac
lateral

500
non-stero Rheumato tion, Madrid,Medicine
2

aT m
800

sprain

of acu ammator erging

score 2 c is ankle
om ion , EUL diclofenac (5.9%) respectively. were
60.6%, median percent times
three or diclofeng of Traume superior idal anti-inflaone of the injuries. Exercise logy, Spain
pin

150
Sport

a lg enT Ankle participants Total pain • Based to placebo mmatory most widely
Expression (RPK10M)

IUM
el
al.c Centre Medicine,

Expression (RPK10M)
a day ac gel &
71.1%
d O
open
POS op
age for (D-G) for Health Cambridg

te mu
drugs,
urn
Ability in used
to scientifi Dov
in each
o
relief and 68.9% reductio on access

y
14 days, has been its efficacy providing Performan
an 25.0 and is

sculos drugs in tion to no

d SYM
e
points Measur

mus riThm
was and
epre
mrojo
group,
for the ns in Visual with
pain Preventive ce, Cambridg
3

400
Experimental protocol search driTE
reporte
and lower for T-O, e Activitie
5 treatment modalities Analysis managem used for and relief.
respecti c and
ss
600

d by tolerabili
ELLI
:
many and e, UK
s of 12 (8.5%),T-O, T-G Ana- Sports medical

, Ma
vely. Medicine, Rehabilita

100
ent of
w.c SAT bound T-G Daily musculos years in the
ty, Traumee

orders tural
diclofen
Re Living Median improve 7 (5.0%)and D-G
A 13 c
research
confide and D-G
f
University Technical tive

the ma
What’s
M 20 u
0H keletal 12H 24H
Germany Munich, 36H 72H 96H 120H 192H
ww
o reporte ac for reducin
kelet nstero
l
cal
lo
groups, subscal
r
nce
FRO Diso
• The new disorders Munich,
e score ments
edi
and
Wounding control S g pain intervals Hours post-injury Rev

sue Dis le for a Na

d total respecti
1 Differential gene DING LAR
r D e s k e l e Ta
4

1 Anesthetizent M al inj
8 . DEYRE

300
mouse in
reporte natural
Iew

uries nagemen idal

pain and demons vely. were Foot Traumee medicati Clinic,
d Mann–W 26.2, and
Conclu by 31/447 relief and
CEE
function trated Correspo Madrid,
400

rre EU 1% in l gel are ons,

hitney 26.2 and

ft Tis
al improve non-infe Traumee Spain
Cu expressionPRO m, extent sions: T-O participants
normal reducing as effective This Dr Carlos ndence

rs
effect
Tr14 injection riority l ointment article Gonz to:

Ro
Chris
l
of Traume sizes Figure
individua
function ment.
6.ls Transcriptional systems anddifferentially affectedde Vega, by Tr14 and diclofenac therapy. Induction of Nrf2 by Tr14 in injured skin.

n in So Potential
m:
t
Internat
Medical was

posiu
as D-G and pain as diclofena alez
in acute T-G decreas(6.9%). Treatme ing. At • In a tian with and ionalDirector publishe
fro Adverse 6 weeks, mild-to-m restoring 24 March

200
c gel MEDYR Journal
el d in
particip vs.
RNA was levelsmulticen ofSchnNrf2, a keyankleregulator ofNumber
the oxidative Sportsof stress
General pathway,
g Dove are shown as a function of time after injury with control, or with
large Clinic, the followin
tedShave dorsal skin
ankle
2 oderate function
ed pain Praxis 2011

matio
nts were events & Rehabilita
sym tre eider
sprain, well in
Tr14 injection + ointment and were and improve ants für Ganzh
200

prin equally (n = 43) Herrsc

effects. tolerated 28020,of times tion Medicine Medicine

d
study,
•Tr14,
Traumeeor diclofenac
with treatment.
sprain.
Intro
lite
Hernani Press
Re hing, ,eitsme Madrid, this

Inflamthedence an ation
well tolerated joint were Münch topical Spainarticle
free of hair well Tel.: 54, journal:
duct
satel
tolerate Germa a low dizin, Traumee + 34 has been
ion function Germa enl Harlac ny; Schönrisk of adverse l Abstr Fax: 91 5360029

100
d. d. local ny can be hing, + 34 viewed

ma
Acute to the Email:act:91 5530414
Topical diclofenac treatmen considere

Conclusions
same Münch Klinik usually cgdv@tel Muscu

einEvi erge dic lateral ankle sprain topical

s:
t d
diclofena option and an effective employefonica.nloskele
t2
en,
froNetworks and gene
Disclosu

rd t Me

Academy of Sciences conference on Resolution of Inflammation,

be the ligament inflam tal
0

s, particu s the et
Th
c for an first-line, JG and res
treating alternativ RICE injuries
3 Abrade shaved arealemen ontology (GO)
mation
Saline control
ng soTar
compl CGV
0H 12H 24H 36H 72H 96H 120H 192H 0H 12H 24H 36H 72H 96H most 120H 192Hlarly e to inflam support . financial
received are
for the Nonste
Witho acute (rest,

aski Mu
ut adequcommon ex, are freque mation ice, compron the rise.
(2017) 54–63
those plant ankle
roidal
Medicine 13
dilti- a
pp Hours post-injury Hours post-injury to chron involv and
sprain. usedand CGV had study; and CS, BW
of Integrative
to submitted to contro anti-inflamm
s su
ate care, muscu First-li
European Journal
for the
ing matio miner treat financial support ession
m e loskele ntly report the swellin
theneon)
ic proble thework
■ Tr14 and diclofenac impact different subsystems drugs in elevati
, and
COX/LOX ement pathways during wound
n and
ith
restric al extrac Biologisch
sympto l pain. atory manag
eding
acute

pain ft tissu es w
ORIGINAL RESEARCH tion tal injury ed to (10). g. Traum
Effecti pain caused ts used
ms, e Heilmittel from Traum
published: 17 Topica and loss such ankle apply GmbH; ms associa (NSAI
ScienceDirectLeukotriene C4 synthase Gamma-glutamyltransferase 1 (converts stratedLTC4 to to LTD4) BW eel
CGV, eel , of
4 Treatce stimul
muscu Heel approa
with Tr14
August 2017
of functi as pain, trauma (1–3). is ®
veness advisory
Leukotriene C4 synthase Gamma-glutamyltransferase 1 (converts LTC4 LTD4) ch to such injurie
for
available at
doi: 10.3389/fmolb.2017.0
Contents lists
l diclofe
rando loskeletal and by repair,
muscu treatin as measured paper
by mRNA multiplevels.
boardi toand CS are a fixed ted
combi with acute
a prepar Ds) are

es of of so tcom
Pro can
0057 Traumeel
presen members ation also
inflam to be an nac has on (2,4).
joint
instab controllead injurie tolerability loskeletal inflam- andHeilmittel
g for Biologisch for le comm limit excess s
7 animals/treatment positive or negative
mised ts the targets nation muscu with

150
Medicine control skeleta mation in effective
been ility, reduct contro
■ Diclofenac,
s have of Traum injurie buts not
of
CGV its efficac
Tr14, GmbH; eaccum
receivedinhibits
Heel
COX-2 mRNA induction
to restore of biolog loskele bioregulatoryonly used
by blocking ive
to downstream PGE2
of Integrative
ions studies
3 ncRNA expression Tr14 in the mobilin pain lled trials,
have ulating
agent consistently

leng ent nt ou
y and
CS and ical tal injurie
effects limit
European Journal
acute fees from
eviden normal
controls Tr14 functio l disorders ankle in reduci
been eel for the consultan
nessHeel GmbH;Biologisch tolerab and s, includ
80

which reported for consultan treatm functio minera

Chal agem patie proach

demon 14). and ce of is also
(6,8). nal capaci (5–7), with sprain and ng pain diclofenac Traum ity of joints swellinproduction. to NSAID e Heilmittelcy
ent ility
in Traum ning l extract ing

olution
- BW
diclofenac in improv has received of muscu random

Expression (RPK10M)
om/locate/eujim lent
to conveeel has also such
g, and demon s in eel’s of regula s, which pain and
www.elsevier.c
Deep Sequen oral
Topica ty, mobil impro other and
as ankle impro strate is ongoin
ingcymobili
Biologisch fees from terms loskele ized action tory

tion res
non-st l diclofe muscu trials,
■ Tr14, butvemen nottsdiclofenac, reduces mRNA levels inwellthe leukotriene mecha synthetic pathway, likely
journal homepage:
vemen and e Heilmittel of reduci tal injurie on aims
nac is ity and
GmbH
Expression (RPK10M)

cing diclofe ntional demon ty, as

man izing eted ap

(6,7,9) ts in lo- BW has g Johnson
and with the to
5 Harvest tissue
Traumeel_Clinica om Transcriptom eroida
usually global patien joint manag strated and knee further to
received broade
Heel
& Johnson; a favora
ng sympto s. Traum as observ inflam nisms.
Analys nac

amma
nal.c interve , and is a l anti-in

100
lSummaries_TAA assessm ts’ few mobility. (17) lectures,establi matory This
60

ement efficac payment n the ble safety

.cmrojouris of
by(15),activating
(11–
SS_EN_68pp_B5 95
e flamm better y equiva an the Nrf2/KEAP2 pathway. ms of eel
inflam has shown
ational proces
efficacy and
includingsh clinica
Murine ntion useful Traum in pain anti-in as its benefit

tes infl
and
r2 ,
_73845_1401.ind
0300-79 tolerat ent advers on for
l eviden profile compa surveillances,
atory speaker

optimti-targ
of theom Wound
ISSN Traum in muscu bench NSAID Biologisch flamm . While mation,
4 Differential splicing - NSAID
d 1 ed than e effects relief bureaus, a speaker

Burmeiste rolled study Effects of a

www loskele mark for
drugs The eel
s (16) GmbH, s. e Heilmittelatory s, curren

Multicompone Healing:
eel � ce
for Baden (12,13 is well t inform of Traum accele rable

0) promo
object and from
Ze14 Visit-7995 (NSAI Keyw Astra agent contin

lfarth
al.c and ent. -Baden (Biolo and effecti
1 Yvonne
d, saline-cont of Tr14
tal injurie pharm contro ive of this ,15–21 tolerated, improving ued researcrating

Infection and Tissue Regeneration.3

0300 Ds) ords: Zeneca, Heel that eel in ve-
, Germa gische Chemie, ation recove
6 Isolate and purify d, randomize lar injections ojournfree cont
is at
acolog
hem ,
ness ). sugges acute muscu

mul
ISSN lled inflam
Multitarget Heilm s. study large multicReferences Traum
40

with Bristol-My Berlin least ry,

Natural Producnt,
h and
MOZArT trial
n (HE-10
ical CGV
WoA double-blin ª 2013 ny) and very developin matory
has received ers Squibb; as effecti ts that develo and
intra-articu mr and 15/01/2014 ittel Traum tolerab eel,
Traum loskeletal
Van Goet co-administered
is a
The 19:12 was drugs inflam
RNA w.c ive
to compaentre, rando pment
tis of the knee:
The Authors. Heel ve and
Bernd safety of
Int J fixed payment
This Clin Pract, both eel, with ility of education g and delivering for mation eel may injury
wwarch A. Smithb , Charles B. KahnTherapy-Tr14
c
1. Porozovmised S, Cahalon Biologisch alL, Weiser M, Branski D,, acute
Lider O, Oberbaum appear M. Inhibition ofand
IL-1beta and TNF-alpha secretion
1 , Emeline
, combi GmbH
50

Intr
atio t
Internatio

Forb,⁎itfull
nation , and administereda conve a homeo re the
is
painful osteoarthri
distributian open presentat be
GmbH;odu
s to

nt medic
October

eed,editing treatment of a
nal
be better considered to
Chêne any on in access 2013, Journal effecti e Heilmittel ions for muscu
l therap from medicresting and activated ctio Heel human immunocytes byloskel the homeopathic medication as Traumeel S. Clin Dev Immunol
restora ntiona pathic
t. Vis , Robert
article 67, 10, of Clinical of ve- Inacti
den, Germ
any medium, topica BW

1 , Gérald
20

SpRNA
5 b
, Donald INE P. Reitberg under 979–989 Practice to-mo tion
of functi lly in
for developinhas received
vity n etal
tolerat
ed than
ten
thy in the treatment
mpone
provided the terms derate ation, benefi education is
, Eve del Rio O ONL the reducty,2004;11(2):143–9. recognpayment injurie
Baden-Ba7 time points + 0H
1 . g and

Wanecq Dubourdeau
published
the originalof the doi: 10.1111
7 Generate and
Georges St. diclofe
Carlos J. Lozada CMR con States Laurent III acute on ts ofal presentatdelivering
ized s, nonste
free 1400 N.W. 12th
FL 33136, United
Creative /ijcp.122by John ankle in indivi 2. ion nac, Johnson

GmbH, Cahours d
of pain physic regula as anMR, Eremina T, Wahlestedt C, Urcuqui-Inchima

A multico
1 , Estelle 2
1, 2
St Laurent G,otherShtokalo D, Tackett S, Seilheimer B, McCaffrey
GO TO
Avenue, Miami, Dmitry Shtokalo , Bernd Seilheimer work Common Wiley & Johnson; ions for roidal
Moskowitz is properly 19
sprain duals with al there r physic impor
Roland W.
& Sons

sed at 4
1, 5, 6 3
, Michael Tackett that could activit
relationsh
tail cDNA , Yuri Vyatkin anti-
s

r , Marc
School of Medicine, cited, Attributio pation
ittel Heel
United States

Guigné
Miami Miller and Bridgewater, NJ 08807,
Timothy A. McCaffrey al activit tantthe
1, 6 1 Ltd. are no
. Diclof TA, mild- Kapranov P.
in Intronic onRNAs constitute major fraction of the non-coding RNA in mammalian cells. BMC
ips
appear oryactivities
, Maxim Ri , Jianhua Zhou
0, 12, 24, 36, 72, 96, 120, and 192 hours University of
hive Hollywood, FL 33021, United Avenue, Cleveland,24H
United States
the use n-NonCo predic
1, 6
0

7
, Ian Toma to have most
0

1, 4

Seilheimegische Heilm
* influenced

was increa
Brook Drive, States OH 44106, , 4 is non-com mmercia enac comm sports y are tor of
1 , Charlotte
Division of Rheumatology,
Services, LLC,
135 Walters a , Dan Jones 3 the days
Genomics 2012;13:504.
registratsubmittedand
2 , Bernd
and Trial
mercial l-NoDeriv morta
1
0H 12H 24H 36H 72H 96H 120H 192H was on can have well
arc Street, Medical0HCenter, 11100 Euclid12H 36H 72H St. Laurent Institute,
96H Vancouver,120H 192H
Baillif of SPMs Vehicle
Rio Pharmaceutical 4700-C Sheridan b
and no s License, day,NCT0106 injurie work. other docum lity
2 Biolo fullHospitals Cleveland
Rheumatology, WA, United ion
Hours post-injury
GmbH, Baden-Baden,
Hours post-injury accou s are physic substa ented. and morbi
nt ein - esis South Florida c
Germany, Nantong States, SeqLL, Inc. Woburn, modifica which 6520
e 8 6 RvD2
Disclosures ment and nt foracknowledgements
University 2

Synth Sequence on Helicos/ Systems Biology HE-100 at the al activit ntial

Krömmelb use, Franc
Division of Rheumatology, For
Novosibirsk, 4
Corres tions or adaptatio permits
Vince
1
d MA, United States, A dity,

*
University, Nantong,
Russia, AcademGene of
aim LLC,this, 6 use sprain about ankle, health mode
Schön ponden and the
3
with age. The which ies increa
China, A.P.Ershov Biologische and

group.
ACT
University, Washington, 5

tment Institute of Informatics Heilmittel Heel innate 20% benefi rate

Novosibirsk,
s. Moreo jointly
Natascha SAS, Toulo SeqLL SMS E ABSTR condition increasing safety ofDC, ce: Christians are made.
The studies were
factor funded of by all Biologische , with Heilmittel Heel GmbH andntthe St. Laurent Institute. Professor
Russia, Division 1
co-administered Harlac Klinik amou
phil recrui
7
and painful
United States
ses ts. Howe
280 samples F O Figure 3. Transcriptional changes in COX/LOX
knee is a during
prevalent Tr14 and diclofenac therapy. Using RNAseq of abraded mouse skin,Genomic the levels Figure 4. Transcriptional systems differentially affected by Tr14 and diclofenac therapy. RNA levels of 3 major leukotriene synthetic
and of Systems, 2
Münch
s, such ver, there sports injurie an incide the risk
Ri for T LIN
100 the efficacy Medicine, The
Harlac hingPr n Schneid are elderl
ICLE I N of the was to evaluate moderate-to-severe George Washington ver, particHeel of
cs of neutro t 6 hours.
ivatAm en erTim McCaffrey
1 Ambiotis
LxA4 A RON
of COX-2 and LTC4
Osteoarthritis
synthase wererandomized quantified controlled trial,
by RNAseq during
(OA) experiencing
Wound
control, Tr14,healing
and diclofenac treatment. RNA levels are shown over enzymes are shown during 8 days (192 hrs) post-injury. 81547 hinger y has received as speaker honoraria
are additi from nce Biologische Heilmittel
of injury GmbH. The authors are deeply
Str 51, bulanz , Gener and prone in people
Introduction: osteoarthritis 979 s and

Results vely modifies kineti

of 1
RO with knee i-
reduce
involves the
80 first well-controlledZeel (Ze14) in patients meeting Tel +49 Münch
indebted usuall sadly per 100,0 .during The
providto the ally,vision of Dr Georges who St. Laurent, who y comp passed mostthe completion of these studies.
Edited an onal
by almos
Eligible patients orchestrated
CM Keywords: medicinal product 8 days (192 hrs)the
by: 1
such as en, Germa
the princito falls.
(Ri)Figure 1. Study methodology
gain to outline. post-injury.
(Tr14) and Joseph Curran, trial.
hemostasis, Tr14/Ze14 1
response that Fax 89 6211 are overw risks of

*
00
TO Traumeel Université de
randomized,
saline-controlled
to 3, weekly
cellular
intra-articular 1)
(daymigration, engages multiple +49 4060 ny e
and the symptomati muscu rise mode people 4

tion index as the time

15 Genève, inflammation. email 89

condition:
60 Homeopathic eight,
GO multi-center, from baseline ple of
Switzerland extracellular chschn6211 4062
00 positi rate liga-a
injections pain. were randomized processes,
was a double-blind, criteria for knee OA knee pain change Using throug loskeletal
pg/ml

matrix synthesis,
defined to the control
3
Intra-articular a murine
included c relief the manag
Methods: This
EULAR, Amsterdam, The Netherlands, 13–16 June, 2018
Reviewedendpoint was pre-in
ns the resolu
endpoints eider@
HE-1 model

1. St. Laurent G, Toma I, Seilheimer B et al. Differential effects of tr14 versus diclofenac on
Knee joint was of Rheumatology Primary efficacy by: Pain Subscore. mappedSecondary of cutaneous and in particular, healin jury h excess injury
from 12 h to(PhGA)
ound is
40 of the knee American College (n = 113) injections. (PGA) and physician wound repair, schoen g. 6,7 so that ement
Tanja WOMAC 8 and In this level of ive load, from
l and shorte
by theDominko, days post-injury, -klinike
Osteoarthritis and patient
multi-target monly
ared 10 (n = 119) or
saline Worcester
as measuredPolytechnic50-foot walk test, adverse events
(AEs), the transcriptome functi a return of acute
biochemica s igated comp
Pain visit (day 99), natural and in response n.de used respec
% comp
controlled trial
Institute, product, Tr14. or who
t, nonste on is regain to activit musculoskel
submit
20 and subscores, examinations,
published meta-analyses
to end-of-study Index total United treated knee there Using single-molecule to a multicomponen to functi to limit
an invest number to 50
your
pg/ml

Randomized were with

WOMAC OA by vital signs,States hoc for consistency Dovepre manuscrip

al active
clear
tion ostasi measures of temporal changes t, on. 7 inflam ed witho y and rehab
8

Tr14 was assessed post RNA sequencing ss t | www.dovep roidal etal

to home
Safety University Cuncong Zhong,
Howe

Introduc inflammation is tissues to returnthat predominate

were calculated
a norm
pathways, and Tr14/ matio ilitatio injuries is
DOI:
in known transcripts
global assessments. n and anti-inflamm ut overtl
0 sizes primary endpoint (RNA-seq), 10.2147/IJ

neutrophil
Traumeel use. Effect of
ress.com
ver, these
5 Kansas, United For theadditional
4

nd Time (hours) medications novel related to wound

States −12.40, GM.S1670
differences. transcripts of y comp n can to
drugs to contro
WOMAC treatment
-T 50 compou CI for difference:
concomitant baseline
treatments. no significant modulated
95%
pain relief over both coding healing 9
atory
Ze14 of standard-of-care were randomized with
*Correspondence: p = 0.0383, efficacy for Interna are not l pain, drugs romis begin, 5
of ed Ri = T 50 vehicle
vs. −25.5; response transcripts related and non-coding
>100
tors patients (−32.0 significant the treatment. © 2011 tional Journal and ing tissue
Resolution enables inflam
Zeel Timothy genes. Tr14 (NSA
8

NPD1 Results: 232 superior to

saline to wounding,
related towound alway
lized Pro-
A. McCaffrey statistically to key wound
in media fatty Vehicle
0 measures showed
Ze14 was significantly50-foot walk pain mcc@gwu.edu the most
no serious adverse events contraction, repair pathways, which Schneid of s well appear to IDs)
are
4

Time (hours) permits er, publishGenera

by a switch
profile showed Day 85. and
precise and cytokine tolera facilit
that that Specia nsaturated
and
29, 71 and
such as
ate the com-
process
−0.35). WOMAC (except Day 29). Safety on Days to saline-control
comparedcomprehensive response. The l Medicin ted and
panied
HE-100 responsepain torelief
unrestr er

cox/lox pathways revealed by rnaseq. Ann Rheum Dis. 2018;77:238–239. THU0021. 

15–99 for Tr14/Ze14 comparable characterization results provide icted and licensee e 2011:4 return
was shown
study days skin these were altern
of polyu study we
1000
significant improvement
Specialty section:provided significant relevant, sincedamage, to date of the
and is accomRecently it s), derivatives
1 Tr14/Ze14 understanding repair, and noncom Dove 225–23 atives
RvD5 PhGA indicated This article was
intra-articular effect sizes
were clinically multicomponen transcriptome’s mercial may

*
In this study, Medica 4
ss. In this arget
over.indd submitted benign. the wound

*
profile was t natural product
to
800 Conclusion: period. Treatment possible to intervene repair process, and the use,
The safetybe providel Press Ltd.
tes.
ment2-C
the observation therapy. By
in exuda Mediators (SPM in this proce
9-Supple throughout treatments.RNA, effects of natural
a section
for standard-of-care more effectively d the This

nent multit
of
CMRO-2
250 600 to those reported Frontiers in Molecular the journal in diseases involving products, it original is an Open
tial a self-
Keywords: should
resolving As), are essen a multicompo
pg/ml

Biosciences wound healing, work Access

and in- aberrant repair.
tion, using
RNA-seq, Traumeel is proper
Received: 13 transcript profiling article 225
200 400 March 2017 where degenerativematrix pro- (Tr14), multicomponent, ly cited.
(PUF s of n resolu
Accepted: 02
bone and
synovium,
Activation
of
OA is
multitarget,
acids the effect inflammatio
August 2017 natural products,
prominent.
l in mice.
subchondral
Published: are both role.
150 200 processes
17 August 2017 play a pivotal TGF-ß1,
[4] seems to of pain,
investigated HE-100, in peritonitis mode
pg/ml

flammatory INTRODUCT
8

[3] and macrophages appearanceION of typical symptoms by ima-

0 Laurent teinases
Deep
Citation:
100 with the function, supported

2. St. Laurent G, Toma I, Tackett M, et al. Differential effects of tr14 versus diclofenac on
pre-
4

Time (hours)1. Introduction with St.

medication san-induced
diagnosed
reduced joint
G III, Seilheimer
common condition
50 (OA) is a very population
Tackett
is estimated
commonly
to M, Zhou J, Shtokalo
stiffness
B, Theand
afterD,inactivity
cellular and physiological
the joint [5]. of pain and im- sequenc
zymo Knee osteoarthritis Globally, 3.8% of the in thein efforts events
analysis
Vyatkin Y, Ri
age [1]. The
limited
50 years of
M, Toma I, Jones D andof
changes alleviation
to understand that comprise
ing tran
8

treatment include pharmacological

with age. McCaffreyging
findings intervention the wound healing
peaking at around that OA increased
the biological
valence rising with as atherosclerosis,
OA
0
with prevalence Sequencing
TranscriptomeThe
Deep of
TA (2017)goals
[6]. Forare understood mechanisms process
of chronic disease. remain paramount of the scriptom
4

Time (hours) ≤ 0.05 age cancer,status

be affected, Study demonstrated to 44% in patients Analysis of functional the importance in the context Major versus eff
HE-100 diclofena ect of Trau
*p-value provement of of aberrant wound
than age 70,
e
Osteoarthritis Murine Wound Healing: of the inflammation diseases, such
cartilage,
ign
tumors as “wounds
me point, Framingham

ml/kg.
in patients younger
Effects of a repair (Ross,
condition involving system and
Multicomponent,

ental Des ntration of 1.5 for 6 days. ion

that do not heal” 1993). Even in
group/ti age, from 27% is a complex
Multitarget Natural
(Dvorak, 1986). wound healing has led authors
older [2]. OA
Recent advances om (R.A. Smith), action meel
in wou c therape
6 animals/ 80 years or
Product Therapy-Tr14. in systems
map of inflammation, biology have
RAS.statistics@gmail.c to describe

Experim
Front. Mol. Biosci. t (D.P. Reitberg), catalyzed
Ri (h) 00 a broad transformation in
in a conce i.p. once daily last inject T 50 (h) HE-1author.
doi: 10.3389/fmolb.2017.0
(E. del Rio),
4:57.
dreitberg@prodigy.ne example, the particular, the
discovery of importance of in the conceptual nd hea utic [THU0
hesis thatCorresponding
eve@riopharma.com 0057 the resolvins its temporal St Lauren

pro-resolving lipid mediators revealed by RNAseq. Ann Rheum Dis. 2018;77:1237–1238.

- have established
was tested ling
the Tmax (h)
(C.J. Lozada),
⁎
om (R.W. Moskowitz). GmbH, Germany. the process of and their actions and spatial evolution. (TR 441
istered
HE-100 e were admin 12-13 hours after indicated time
Shtoka t G 1,Toma
IN 14) AN ] RIS
clusion rt the hypot
clozada89@gmail.com
15.485 E-mail addresses: Heilmittel Heel “resolution” within the inflammation For
Ψ 501 (cells)
rolliemoskowitz@aol.c
4 5.847 (C.B. Kahn), names of Biologische
as a defining lo D 1,3
, Seilhe I , Tacket
2

Ψ max (cells)
cbk3161@yahoo.com are registered trade event between system PA K-B
of the 9.638
Con s suppo TIE D ZEE EN
6 Zeel “acute” and “chronic” tWI
san. At
dd
Traumeel and
and vehicl a time lapse
MR
ard.
Frontiers in Molecular
imer
tes were 6 ver.in 3.3x10
t6 license
1

inary result n resolution:

B , McCaff, Zhou J
1
TH
the CC BY-NC-ND
4 Biosciences 4
NT
by almos 016/j.eujim.2017.07.0 article under OA S WI L® (ZEEFIT
| www.frontiersin.org

ed by zymo neal exudaLC-MS/MS.

6.6x10 t2-Co
rey TA , Vyatkin
1

is an open access bm
July 2017
-
ing 05 Accepted 26

These prelim matio GmbH. This

lemen

tion indexhttp://dx.doi.org/10.1 14) OF CO

Vehicle Supp 25 July 2017; C.Y ,
by Elsevier
6
Follow OF
2 1

was induc nized, perito

revised form
1
TH
and
5.8x10
ote inflam © 2017 The
April 2017;
Author(s). Published-ND/4.0/).
Received in
j.com Loza
TH
E MO
phil resolu
O-29- da,
peritonitis were eutha flow cytometry 24 HE-100 me point Received 26
1876-3820/
INT
group at may prom
CMR
ns.org/licenses/BY-NC
August 2017
| Volume 4 | Rep E. del -AD KN DE
group/ti
(http://creativecommo RA RA-AR MINIS
ved neutro
Article 57
DO rinted
treatment of debris at
Rio,
mice EE
by 6-8 animals/
points, and analyzed (OA TE-
D.
00 impro I: 10.1 TIC
P. Reitb
ed in the
from
s K) TO-SE UL TERED
• HE-1

AB0080. 
nce 136 : Ann
collected is macrophage
erg,
VER AR (IA TRA
were detect ed in the cleara numbers
/ann R.

tment of
Rhe
phages mediators
Smit
hours rheu um E PA UM
se in their
h, R. )
involv d recrui solving IN INJECT EEL
mdi Dis
More macro phages are
W.

sis). Increa
s-20 201 Mos ASS
Macro tion. 00 favore of pro-re 15- 5;74 kow
OC ION
®
hours. (efferocytoimpact on resolu • HE-1 synthesis
eula itz
r.42 ( Supp IAT S
ed site ve stimulated 68 2):4 ED
the inflam have a positi 00
1
The St.
268
• HE-1
Laurent
to
2
The George

believed
Institute

expected
to A.P. Ershov Washing (SLI),
eu
3
One
Institute ton Universi Kendall
lar

3. Baillif V, Guigné C, Wanecq E et al. A multicomponent medication (HE-100) promotes

ound is tion time.
Novosib Square,

*
irsk 630090, of Informa ty Medical

comp . 4
Biologis tics Systems Center,
Cambrid

Heel GmbHrd.
che Heilmitt Russia. ge,
tive nts
Washing MA, USA.

a resolu shorten the resolu

SB RAS,

ledgeme Heilmittel
el Heel
GmbH. 6, Acad. ton DC, USA.
design standa
NPDI
Lavrentj
and gische
preventive recruitment Acknow funded by Biolo
ev pr.,

In this phil ing the

neutro was ed for provid
dampen This study Serhan is thank
N
Charles

inflammation resolution. Poster at New York Academy of Sciences conference 25–26 June.
Publications on Traumeel studies are available
6-8 animals/
group/ti
me point,
*p-value
≤ 0.05

Hans-Heinrich Reckeweg Clinical Case Award

Each year Heel awards health care practitioners with the Hans- Medellín received the Main Award for his case report on the
Heinrich Reckeweg Clinical Case Award. The review committee revascularization and repair of a damaged mucosa in a dog. Andrea
assess numerous applications reporting successful bioregulatory Valero Carvajal from Bogotá received the Runner-up Award for the
therapies in various conditions that physicians and veterinarians case report of successful acne management in an adolescent with
encounter in their everyday practice. a Bioregulatory Systems Medicine approach.
The 2018 winning case reports were awarded to two healthcare Applications for the 2019 Hans-Heinrich Reckeweg Clinical Case
practitioners from Colombia. Juan Carlos Builes Rodríguez from Award are now open. Submission deadline is June 30, 2019. 

Knee osteoarthritis pocket guide

Get in If you have something you’d like to have included in the next
newsletter, or are planning a meeting or participating in a local
The knee osteoarthritis pocket guide has been

touch! congress, please let us know. We’d like to hear from you!
translated into Italian, Portuguese, Russian and Spanish
and can be distributed at Heel educational events.

Disclaimer: For all materials described in this newsletter please ensure that they comply with local laws and regulations before implementation.
For further information please contact: Dr. Beata Bednarz-Wolska, phone: +49 7221-501 134, beata.bednarz-wolska@heel.com
Biologische Heilmittel Heel GmbH, Dr.-Reckeweg-Str. 2-4, 76352 Baden-Baden, Germany, www.heel.com, www.traumeel.com

© 2019 Biologische Heilmittel Heel GmbH

www.heel.com
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical,
photocopying, recording or otherwise without the prior permission of the copyright owner.